VRDN Viridian Therapeutics notches narrow Q4 2025 EPS beat but shares fall 358 percent on lukewarm investor sentiment What currency exposure Beacon Fin BBT Q4 2025 Earnings Fall Short How does Exelixis EXEL PE compare to sector Slight Gain 20260427